Johns Hopkins Center for Psychedelic and Consciousness Research

The first major academic psychedelic research center in the United States, founded by Roland Griffiths in 2019. Johns Hopkins has run landmark clinical trials in psilocybin for depression, tobacco addiction, cancer anxiety, and major depressive disorder. Their research has produced some of the most-cited data in the field, including Matthew Johnson's 80% smoking abstinence result. Active trials enrolling for multiple indications.